BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

751 related articles for article (PubMed ID: 15755898)

  • 21. Natural Killer Cell Functional Activity After 4-1BB Costimulation.
    Navabi Ss; Doroudchi M; Tashnizi AH; Habibagahi M
    Inflammation; 2015; 38(3):1181-90. PubMed ID: 25520217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of NK cells by engineered K562 cells co-expressing 4-1BBL and mMICA, combined with soluble IL-21.
    Jiang B; Wu X; Li XN; Yang X; Zhou Y; Yan H; Wei AH; Yan W
    Cell Immunol; 2014 Jul; 290(1):10-20. PubMed ID: 24859012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
    Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
    J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of 4-1BB (CD137) expression by DNA damaging agents in human T lymphocytes.
    Kim KM; Kim HW; Kim JO; Baek KM; Kim JG; Kang CY
    Immunology; 2002 Dec; 107(4):472-9. PubMed ID: 12460192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.
    Melero I; Johnston JV; Shufford WW; Mittler RS; Chen L
    Cell Immunol; 1998 Dec; 190(2):167-72. PubMed ID: 9878117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.
    Cooper LJ; Topp MS; Serrano LM; Gonzalez S; Chang WC; Naranjo A; Wright C; Popplewell L; Raubitschek A; Forman SJ; Jensen MC
    Blood; 2003 Feb; 101(4):1637-44. PubMed ID: 12393484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
    Chen KH; Wada M; Pinz KG; Liu H; Lin KW; Jares A; Firor AE; Shuai X; Salman H; Golightly M; Lan F; Senzel L; Leung EL; Jiang X; Ma Y
    Leukemia; 2017 Oct; 31(10):2151-2160. PubMed ID: 28074066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
    Finney HM; Akbar AN; Lawson AD
    J Immunol; 2004 Jan; 172(1):104-13. PubMed ID: 14688315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A.
    Eissens DN; Schaap NP; Preijers FW; Dolstra H; van Cranenbroek B; Schattenberg AV; Joosten I; van der Meer A
    Leukemia; 2010 Mar; 24(3):583-91. PubMed ID: 20033055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-15-induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2-A as the only HLA class I-specific inhibitory receptor.
    Mingari MC; Vitale C; Cantoni C; Bellomo R; Ponte M; Schiavetti F; Bertone S; Moretta A; Moretta L
    Eur J Immunol; 1997 Jun; 27(6):1374-80. PubMed ID: 9209487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.
    Shuford WW; Klussman K; Tritchler DD; Loo DT; Chalupny J; Siadak AW; Brown TJ; Emswiler J; Raecho H; Larsen CP; Pearson TC; Ledbetter JA; Aruffo A; Mittler RS
    J Exp Med; 1997 Jul; 186(1):47-55. PubMed ID: 9206996
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
    Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
    Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
    Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
    Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of NK cells through the 80-kDa TNFR (CD120b).
    Mason AT; McVicar DW; Smith CA; Young HA; Ware CF; Ortaldo JR
    J Leukoc Biol; 1995 Aug; 58(2):249-55. PubMed ID: 7543923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
    Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
    Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells.
    Tayebi H; Kuttler F; Saas P; Lienard A; Petracca B; Lapierre V; Ferrand C; Fest T; Cahn J; Blaise D; Kuentz M; Hervé P; Tiberghien P; Robinet E
    Exp Hematol; 2001 Apr; 29(4):458-70. PubMed ID: 11301186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.